Pre-IPO Qyuns Therapeutics (PHIP Updates) - Some Points Worth the Attention
Qyuns is overvalued due to gloomy commercialization outlook.Qyuns may even find it hard to recover the cost of pipeline. Investors could trade and...
Pre-IPO Hangzhou Jiuyuan Gene Engineering (PHIP Updates) - The Future Prospects Are Not Optimistic
Jiuyuan's growth momentum is stalling due to VBP. Guyoudao and JY29-2 face competition and uncertainty. Market value may surpass Qyuns. Future...
Pre-IPO Qyuns Therapeutics - Conservative About the Outlook
Qyuns’s pipeline lacks competitiveness, facing fierce competition.Together with bleak internationalization outlook, peak sales have obvious...
ECM Weekly (5th Nov 2023)- Midea, WuxiXDC, Cello, Honasa, Qyuns, Ecopro, Lalatech, Mankind, TWE, VNT
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
Qyuns Therapeutics (荃信生物) Pre-IPO: Mixed View on Two Core Products
In this note, we look at fundamentals of Qyuns Therapeutics. We examined the two core products, QX002N and QX005N. We have mixed view on its...
No more insights